BACKGROUND: Substantial time elapses before patients with hilar cholangiocarcinoma (HCC) receive surgical treatment because of time-consuming preoperative staging and other interventions, including biliary drainage and portal vein embolization. Prolonged times potentially lead to unresectability and the formation of metastases, yet these issues have not been investigated previously in HCC. This study aimed to evaluate the time between onset of symptoms and the provision of ultimate treatment in patients with HCC and the impact of the length of time on outcomes. METHODS: Delays in the treatment of consecutive patients with HCC were evaluated by contacting general practitioners (GPs) and extracting data from hospital files. Time periods were correlated with resectability, occurrence of metastasis, tumour stage and survival using logistic and Cox regression analyses. RESULTS: Treatment times in 209 consecutive HCC patients were evaluated. The median time from first GP visit until presentation at the tertiary centre was 35 days. Time until treatment was longer when initial symptoms did not include jaundice (non-specific symptoms, P < 0.001). Duration of workup and preoperative biliary drainage at the tertiary centre prior to final surgical treatment resulted in an additional median time of 74 days. No correlation was found between treatment time in weeks and resectability [odds ratio (OR) 1.010, 95% confidence interval (CI) 0.985-1.036], metastasis (OR = 0.947, 95% CI 0.897-1.000), tumour stage (OR = 1.006, 95% CI 0.981-1.031) or survival in resected patients (hazard ratio = 0.996, 95% CI 0.975-1.018). CONCLUSIONS: The time that elapses between the presentation of symptoms and final treatment in patients with HCC is substantial, especially in patients with non-specific symptoms. This time, however, does not affect resectability, metastasis, tumour stage or survival, which suggests that preoperative optimization should not be omitted because of potential delays in treatment.
BACKGROUND: Substantial time elapses before patients with hilar cholangiocarcinoma (HCC) receive surgical treatment because of time-consuming preoperative staging and other interventions, including biliary drainage and portal vein embolization. Prolonged times potentially lead to unresectability and the formation of metastases, yet these issues have not been investigated previously in HCC. This study aimed to evaluate the time between onset of symptoms and the provision of ultimate treatment in patients with HCC and the impact of the length of time on outcomes. METHODS: Delays in the treatment of consecutive patients with HCC were evaluated by contacting general practitioners (GPs) and extracting data from hospital files. Time periods were correlated with resectability, occurrence of metastasis, tumour stage and survival using logistic and Cox regression analyses. RESULTS: Treatment times in 209 consecutive HCC patients were evaluated. The median time from first GP visit until presentation at the tertiary centre was 35 days. Time until treatment was longer when initial symptoms did not include jaundice (non-specific symptoms, P < 0.001). Duration of workup and preoperative biliary drainage at the tertiary centre prior to final surgical treatment resulted in an additional median time of 74 days. No correlation was found between treatment time in weeks and resectability [odds ratio (OR) 1.010, 95% confidence interval (CI) 0.985-1.036], metastasis (OR = 0.947, 95% CI 0.897-1.000), tumour stage (OR = 1.006, 95% CI 0.981-1.031) or survival in resected patients (hazard ratio = 0.996, 95% CI 0.975-1.018). CONCLUSIONS: The time that elapses between the presentation of symptoms and final treatment in patients with HCC is substantial, especially in patients with non-specific symptoms. This time, however, does not affect resectability, metastasis, tumour stage or survival, which suggests that preoperative optimization should not be omitted because of potential delays in treatment.
Authors: T M van Gulik; J J Kloek; A T Ruys; O R C Busch; G J van Tienhoven; J S Lameris; E A J Rauws; D J Gouma Journal: Eur J Surg Oncol Date: 2010-11-27 Impact factor: 4.424
Authors: Jean Marc Regimbeau; David Fuks; Yves-Patrice Le Treut; Philippe Bachellier; Jacques Belghiti; Karim Boudjema; Jacques Baulieux; François-René Pruvot; Daniel Cherqui; Olivier Farges Journal: J Gastrointest Surg Date: 2011-01-20 Impact factor: 3.452
Authors: Timothy J Kennedy; Adam Yopp; Yilin Qin; Binsheng Zhao; Pingzhen Guo; Fan Liu; Larry H Schwartz; Peter Allen; Michael D'Angelica; Yuman Fong; Ronald P DeMatteo; Leslie H Blumgart; William R Jarnagin Journal: HPB (Oxford) Date: 2009-08 Impact factor: 3.647
Authors: Maria Ramos; Magdalena Esteva; Elena Cabeza; Carlos Campillo; Joan Llobera; Antonio Aguiló Journal: Eur J Cancer Date: 2007-10-10 Impact factor: 9.162
Authors: Anthony T Ruys; Steven van Haelst; Olivier R Busch; Erik A Rauws; Dirk J Gouma; Thomas M van Gulik Journal: World J Surg Date: 2012-09 Impact factor: 3.352
Authors: Robert Js Coelen; Joost Huiskens; Pim B Olthof; Eva Roos; Jimme K Wiggers; Annuska Schoorlemmer; Otto M van Delden; Heinz-Josef Klümpen; Erik Aj Rauws; Thomas M van Gulik Journal: United European Gastroenterol J Date: 2016-09-30 Impact factor: 4.623
Authors: Jan Nilsson; Sam Eriksson; Peter Nørgaard Larsen; Inger Keussen; Susanne Christiansen Frevert; Gert Lindell; Christian Sturesson Journal: Acta Radiol Open Date: 2015-05-15
Authors: Benjamin Gravesteijn; Eline Krijkamp; Jan Busschbach; Geert Geleijnse; Isabel Retel Helmrich; Sophie Bruinsma; Céline van Lint; Ernest van Veen; Ewout Steyerberg; Kees Verhoef; Jan van Saase; Hester Lingsma; Rob Baatenburg de Jong Journal: Value Health Date: 2021-03-05 Impact factor: 5.725